Foghorn Selling General Administrative vs Total Current Liabilities Analysis

FHTX Stock

USD 7.99 0.20 2.57%

Foghorn Therapeutics financial indicator trend analysis is much more than just examining Foghorn Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Foghorn Therapeutics is a good investment. Please check the relationship between Foghorn Therapeutics Selling General Administrative and its Total Current Liabilities accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Foghorn Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.

Selling General Administrative vs Total Current Liabilities

Selling General Administrative vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Foghorn Therapeutics Selling General Administrative account and Total Current Liabilities. At this time, the significance of the direction appears to have strong relationship.

The correlation between Foghorn Therapeutics' Selling General Administrative and Total Current Liabilities is 0.74. Overlapping area represents the amount of variation of Selling General Administrative that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Foghorn Therapeutics, assuming nothing else is changed. The correlation between historical values of Foghorn Therapeutics' Selling General Administrative and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling General Administrative of Foghorn Therapeutics are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Selling General Administrative i.e., Foghorn Therapeutics' Selling General Administrative and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

0.74

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Selling General Administrative

Total Current Liabilities

Total Current Liabilities is an item on Foghorn Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Foghorn Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Foghorn Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Foghorn Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Foghorn Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.Selling General Administrative is likely to drop to about 19.7 M in 2024. Tax Provision is likely to drop to about 2.3 M in 2024

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	7.5M	3.3M	3.5M	3.9M
Interest Income	2.6M	5.7M	10.6M	11.1M

Depreciation And Amortization Interest Income

Foghorn Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Net Working Capital
Total Assets		0.86	0.43	0.63	0.55	0.89	0.73	0.93	-0.48	-0.8	0.78	0.7	0.94	0.73	0.71	0.89	0.85	0.8	0.73	0.8	0.94	0.93	0.49	0.96	1.0	0.99
Short Long Term Debt Total	0.86		0.54	0.48	0.68	0.65	0.88	0.98	-0.27	-0.73	0.76	0.57	0.98	0.54	0.62	0.92	0.81	0.85	0.53	0.99	0.92	0.69	0.66	0.78	0.82	0.82
Other Current Liab	0.43	0.54		0.5	0.8	0.12	0.63	0.52	-0.56	-0.03	0.14	0.61	0.53	0.46	0.76	0.39	0.49	0.23	-0.19	0.51	0.39	0.19	0.8	0.27	0.4	0.43
Total Current Liabilities	0.63	0.48	0.5		0.11	0.66	0.18	0.55	-0.95	-0.64	0.67	0.98	0.6	0.98	0.59	0.57	0.84	0.61	0.07	0.46	0.63	0.71	0.06	0.69	0.63	0.62
Total Stockholder Equity	0.55	0.68	0.8	0.11		0.16	0.91	0.65	-0.09	-0.06	0.1	0.26	0.63	0.14	0.7	0.47	0.34	0.26	0.22	0.62	0.47	0.23	1.0	0.32	0.52	0.57
Other Liab	0.89	0.65	0.12	0.66	0.16		0.42	0.76	-0.5	-0.89	0.88	0.66	0.78	0.78	0.48	0.85	0.83	0.79	0.78	0.63	0.89	0.99	0.1	0.98	0.9	0.87
Net Tangible Assets	0.73	0.88	0.63	0.18	0.91	0.42		0.86	-0.06	-0.41	0.41	0.34	0.83	0.27	0.58	0.71	0.56	0.51	0.48	0.85	0.73	0.46	0.89	0.57	0.7	0.73
Property Plant And Equipment Net	0.93	0.98	0.52	0.55	0.65	0.76	0.86		-0.35	-0.79	0.81	0.64	1.0	0.63	0.64	0.95	0.87	0.86	0.61	0.97	0.97	0.79	0.61	0.87	0.9	0.89
Net Debt	-0.48	-0.27	-0.56	-0.95	-0.09	-0.5	-0.06	-0.35		0.41	-0.45	-0.93	-0.41	-0.92	-0.56	-0.36	-0.7	-0.35	0.1	-0.25	-0.44	-0.55	-0.05	-0.52	-0.48	-0.48
Retained Earnings	-0.8	-0.73	-0.03	-0.64	-0.06	-0.89	-0.41	-0.79	0.41		-0.95	-0.64	-0.81	-0.73	-0.27	-0.84	-0.87	-0.88	-0.65	-0.75	-0.9	-0.88	-0.01	-0.9	-0.79	-0.75
Accounts Payable	0.78	0.76	0.14	0.67	0.1	0.88	0.41	0.81	-0.45	-0.95		0.65	0.82	0.74	0.38	0.92	0.89	0.94	0.6	0.79	0.91	0.86	0.07	0.89	0.76	0.71
Cash	0.7	0.57	0.61	0.98	0.26	0.66	0.34	0.64	-0.93	-0.64	0.65		0.69	0.98	0.64	0.61	0.88	0.61	0.1	0.55	0.69	0.71	0.22	0.72	0.7	0.69
Non Current Assets Total	0.94	0.98	0.53	0.6	0.63	0.78	0.83	1.0	-0.41	-0.81	0.82	0.69		0.68	0.66	0.95	0.89	0.87	0.59	0.96	0.97	0.81	0.59	0.88	0.91	0.9
Non Currrent Assets Other	0.73	0.54	0.46	0.98	0.14	0.78	0.27	0.63	-0.92	-0.73	0.74	0.98	0.68		0.58	0.65	0.9	0.64	0.23	0.52	0.73	0.81	0.09	0.79	0.73	0.71
Other Assets	0.71	0.62	0.76	0.59	0.7	0.48	0.58	0.64	-0.56	-0.27	0.38	0.64	0.66	0.58		0.59	0.55	0.54	0.27	0.53	0.57	0.58	0.68	0.59	0.71	0.73
Long Term Debt	0.89	0.92	0.39	0.57	0.47	0.85	0.71	0.95	-0.36	-0.84	0.92	0.61	0.95	0.65	0.59		0.88	0.92	0.67	0.92	0.97	0.85	0.44	0.91	0.86	0.84
Cash And Short Term Investments	0.85	0.81	0.49	0.84	0.34	0.83	0.56	0.87	-0.7	-0.87	0.89	0.88	0.89	0.9	0.55	0.88		0.82	0.41	0.82	0.93	0.84	0.3	0.89	0.83	0.81
Common Stock Shares Outstanding	0.8	0.85	0.23	0.61	0.26	0.79	0.51	0.86	-0.35	-0.88	0.94	0.61	0.87	0.64	0.54	0.92	0.82		0.59	0.85	0.89	0.81	0.23	0.85	0.78	0.75
Non Current Liabilities Total	0.73	0.53	-0.19	0.07	0.22	0.78	0.48	0.61	0.1	-0.65	0.6	0.1	0.59	0.23	0.27	0.67	0.41	0.59		0.49	0.68	0.76	0.17	0.76	0.74	0.72
Other Current Assets	0.8	0.99	0.51	0.46	0.62	0.63	0.85	0.97	-0.25	-0.75	0.79	0.55	0.96	0.52	0.53	0.92	0.82	0.85	0.49		0.91	0.65	0.6	0.75	0.76	0.75
Other Stockholder Equity	0.94	0.92	0.39	0.63	0.47	0.89	0.73	0.97	-0.44	-0.9	0.91	0.69	0.97	0.73	0.57	0.97	0.93	0.89	0.68	0.91		0.9	0.42	0.95	0.92	0.9
Total Liab	0.93	0.69	0.19	0.71	0.23	0.99	0.46	0.79	-0.55	-0.88	0.86	0.71	0.81	0.81	0.58	0.85	0.84	0.81	0.76	0.65	0.9		0.16	0.99	0.94	0.92
Net Invested Capital	0.49	0.66	0.8	0.06	1.0	0.1	0.89	0.61	-0.05	-0.01	0.07	0.22	0.59	0.09	0.68	0.44	0.3	0.23	0.17	0.6	0.42	0.16		0.27	0.47	0.51
Property Plant And Equipment Gross	0.96	0.78	0.27	0.69	0.32	0.98	0.57	0.87	-0.52	-0.9	0.89	0.72	0.88	0.79	0.59	0.91	0.89	0.85	0.76	0.75	0.95	0.99	0.27		0.96	0.94
Total Current Assets	1.0	0.82	0.4	0.63	0.52	0.9	0.7	0.9	-0.48	-0.79	0.76	0.7	0.91	0.73	0.71	0.86	0.83	0.78	0.74	0.76	0.92	0.94	0.47	0.96		1.0
Net Working Capital	0.99	0.82	0.43	0.62	0.57	0.87	0.73	0.89	-0.48	-0.75	0.71	0.69	0.9	0.71	0.73	0.84	0.81	0.75	0.72	0.75	0.9	0.92	0.51	0.94	1.0

Click cells to compare fundamentals

Foghorn Therapeutics Account Relationship Matchups

Foghorn Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	22.3M	255.6M	519.8M	404.9M	285.9M	280.8M
Short Long Term Debt Total	16.6M	82.0M	58.3M	51.5M	45.1M	47.8M
Other Current Liab	450K	5.2M	2.6M	5.0M	(84K)	(79.8K)
Total Current Liabilities	12.7M	18.8M	48.7M	336.8M	58.4M	87.8M
Total Stockholder Equity	(88.0M)	146.2M	96.9M	112K	(77.2M)	(73.3M)
Net Tangible Assets	(88.0M)	146.2M	96.9M	112K	128.8K	122.4K
Property Plant And Equipment Net	3.7M	62.3M	56.1M	49.4M	42.9M	39.7M
Net Debt	1.6M	(10.8M)	(42.8M)	(294.3M)	(35.3M)	(37.0M)
Retained Earnings	(94.1M)	(162.9M)	(264.3M)	(373.1M)	(471.6M)	(448.0M)
Accounts Payable	3.4M	3.7M	3.8M	5.4M	6.3M	4.5M
Cash	15.0M	92.8M	101.1M	345.8M	80.3M	123.8M
Non Current Assets Total	5.5M	64.9M	60.2M	59.1M	45.7M	43.6M
Non Currrent Assets Other	11K	842K	2.4M	8.0M	2.8M	2.7M
Other Assets	1.7M	2.6M	4.1M	4.1M	1.0	0.95
Cash And Short Term Investments	15.0M	185.8M	154.3M	345.8M	234.1M	178.7M
Common Stock Shares Outstanding	36.8M	36.8M	37.2M	41.6M	42.0M	39.2M
Liabilities And Stockholders Equity	22.3M	255.6M	519.8M	404.9M	285.9M	280.8M
Non Current Liabilities Total	97.7M	90.6M	374.2M	68.0M	304.7M	185.9M
Capital Lease Obligations	1.5M	62.3M	58.3M	51.5M	45.1M	40.1M
Other Current Assets	1.4M	9.8M	5.3M	5.6M	6.1M	5.2M
Other Stockholder Equity	6.1M	309.1M	361.1M	377.2M	395.2M	266.4M
Total Liab	110.4M	109.4M	422.9M	404.8M	363.1M	273.7M
Net Invested Capital	(72.9M)	165.8M	96.9M	112K	(77.2M)	(73.3M)
Property Plant And Equipment Gross	3.7M	19.5M	61.4M	58.0M	54.9M	36.6M
Total Current Assets	16.9M	190.7M	459.6M	345.8M	240.2M	237.1M
Accumulated Other Comprehensive Income	(86.6M)	(7K)	(10K)	(4.0M)	(826K)	(867.3K)
Net Working Capital	4.2M	171.8M	410.9M	296.2M	181.7M	202.0M
Property Plant Equipment	3.7M	62.3M	56.1M	49.4M	56.8M	38.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Foghorn Stock Analysis

When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Foghorn Selling General Administrative vs Total Current Liabilities Analysis

Selling General Administrative vs Total Current Liabilities

Selling General Administrative vs Total Current Liabilities Correlation Analysis

Correlation Coefficient

Selling General Administrative

Total Current Liabilities

Foghorn Therapeutics fundamental ratios Correlations

Foghorn Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Foghorn Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Foghorn Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Net Working Capital	+ 1.0	Total Current Assets
Net Working Capital	+ 0.99	Total Assets
Other Current Assets	+ 0.99	Short Long Term Debt Total

Accounts Payable	- 0.95	Retained Earnings
Net Debt	- 0.95	Total Current Liabilities
Cash	- 0.93	Net Debt
Non Currrent Assets Other	- 0.92	Net Debt
Property Plant And Equipment Gross	- 0.9	Retained Earnings
Other Stockholder Equity	- 0.9	Retained Earnings